Potential Diagnostic and Prognostic Value of Neutrophil Counts, Neutrophil–Lymphocyte Ratio, Pan-Immunoinflammatory Score, Systemic Immunoinflammatory Index, and Systemic Inflammatory Response Index in Brain Tumors
Open Access
- 21 March 2026
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 16 (6) , 933
Abstract
Background/Objectives: The aim of this study is to investigate the possible association between systemic inflammation parameters and tumor presence in brain tumor patients with high morbidity and mortality rates, to examine the discriminative performance of these markers and, furthermore, to investigate the relationship of these markers with the clinical findings of patients at different time points. Methods: This study included 99 patients with brain tumors as the case group and 99 healthy individuals as the control group. Neutrophil, lymphocyte, monocyte, and platelet levels, as well as indices and ratios derived from these parameters, were compared among the participants. Binary logistic regression and ROC analyses were applied to variables showing significant differences, and the relationship between these variables and demographic and clinical findings was also evaluated. Results: The neutrophil count, neutrophil–lymphocyte ratio (NLR), pan-immunoinflammatory value (PIV), systemic immunoinflammatory index (SII), and systemic inflammatory response index (SIRI) values of the case group were higher compared to the control group. While these parameters were associated with the presence of brain tumors, the highest odds ratio, area under the curve, and specificity were found in the neutrophil count, and the highest sensitivity was found in the SIRI parameter. Some or all of these parameters differed according to tumor type, localization, motor weakness, 3-month adjuvant treatment, 6-month recurrence, postoperative day 1, 3-month and 6-month neurological deficits and 3-month and 6-month Karnofsky Performance Status. Conclusions: These parameters can be considered useful biomarkers that show moderate discrimination in patients with brain tumors and can support clinical evaluation.Keywords
This publication has 33 references indexed in Scilit:
- Systemic inflammation response index predicts overall survival in patients undergoing stereotactic radiosurgery for brain metastasis from non-small cell lung cancerJournal of Radiation Research, 2025
- Assessing the prognostic role of panimmune inflammation in high-grade gliomasClinical and Translational Oncology, 2024
- Et tu neutrophils? The brain reprograms neutrophils to facilitate tumor progressionImmunity, 2023
- The local microenvironment drives activation of neutrophils in human brain tumorsCell, 2023
- Disease-Based Prognostication: Neuro-OncologySeminars in Neurology, 2023
- The Role of Neuro-Inflammation and Innate Immunity in Pathophysiology of Brain and Spinal Cord Tumors2023
- Systemic immune‐inflammation landscape in brain metastasis needing neurosurgical resection: Analysis of 230 consecutive cases in a single centerImmunity, Inflammation and Disease, 2022
- Inflammation-targeted nanomedicine against brain cancer: From design strategies to future developmentsSeminars in Cancer Biology, 2022
- The 2021 WHO Classification of Tumors of the Central Nervous System: a summaryNeuro-Oncology, 2021
- Neutrophil-to-Lymphocyte Ratio: Can It Be Used as an Adjunct Tool to Predict Histopathological Grade of Brain Tumor?Journal of Neurosciences in Rural Practice, 2019